Introduction. Alemtuzumab is a humanized monoclonal antibody against the CD52 antigen. It highly efficacious drug for treatment of relapsing remitting multiple sclerosis (MS). The protocol consists in 2 cycles: 12mg/day i.v. infusions 5 consecutive days and after one-year 3 days. To our knowledge, there single case series literature detailing MS remission cycle Alemtuzumab. Here, we report simi...

BACKGROUND Treatment satisfaction in patients with relapsing-remitting multiple sclerosis (RRMS) may impact adherence and thus clinical outcomes. The objective of this study was to measure the satisfaction of patients with RRMS with injectable disease-modifying therapies (DMTs) and to evaluate the factors associated with treatment satisfaction. MATERIAL AND METHODS In this observational retro...

Interferons (IFNs), first recognised because of their antiviral properties, are a key defence mechanism involved in the control of virus infections. They are small proteins separated by nucleated cells in response to viral infection or other appropriate stimuli, and are thought to act principally on other cells in their immediate vicinity. They are divided into two types: type 1 comprises IFN-á...

INTRODUCTION IN THE TREATMENT OF MULTIPLE SCLEROSIS (MS) DIFFER: treatment of relapse, treatment slow the progression of the disease (immunomodulators and immunosuppression), and symptomatic treatment. THE AIM The aim of this study is to analyze the application of interferon therapy in the treatment of MS-E: Process the disease, patients with multiple sclerosis who have passed the commission ...

Inspector Gregory: " Is there any point to which you would wish to draw my attention? " Holmes: " To the curious incident of the dog in the night-time. " Inspector: " The dog did nothing in the night-time. " Holmes: " That was the curious incident. " Conan Doyle's The Silver Blaze There was a time when a neurologist could choose, rightly or wrongly, to downplay the signifi cance of the fi rst s...

AIM Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This study aimed to evaluate the serum levels of relevant cytokines after therapy with IFN-β formulations in MS patients. MATERIALS & METHODS In this study, blood samples were collected from 70 MS patients undergoin...

Interleukin 17 (IL-17) and its receptor IL-17R1 produced by T-helper cells named Th17 are involved in the pathology of autoimmune diseases. In contrast to the at least partially explained role of IL-17 in pathology of multiple sclerosis, the significance of IL-17R in MS is unclear. Therefore we have studied the expression of IL-17R in the stable phase of multiple sclerosis treated by interferon...